ACCSL Inhibitors
ACCSL Inhibitors encompass a variety of chemical compounds that indirectly inhibit the functional activity of ACCSL by targeting specific signaling pathways or biological processes that ACCSL is directly involved in. The primary mechanisms through which these inhibitors act involve the interruption of kinase signaling pathways that regulate or modulate ACCSL activity. For example, LY294002 and Wortmannin target the PI3K/Akt pathway, which is crucial for various cellular functions, including those processes that may involve ACCSL.
Inhibitors like LY294002 and Wortmannin function through the suppression of PI3K, which is a critical upstream component in the PI3K/Akt signaling pathway. The Akt protein, once activated by PI3K, can phosphorylate various downstream proteins that may include enzymes and regulators of ACCSL. Therefore, when LY294002 or Wortmannin inhibit PI3K, the subsequent phosphorylation of Akt is reduced, which in turn can lead to a decrease in ACCSL activity if ACCSL is a downstream target or is regulated indirectly by the PI3K/Akt pathway.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of the PI3K/Akt pathway, LY294002 prevents the phosphorylation of Akt. Since PI3K/Akt signaling can regulate cellular processes that ACCSL is involved in, the inhibition by LY294002 can lead to reduced activation of proteins downstream of Akt, including ACCSL. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
An irreversible inhibitor of PI3K, Wortmannin impedes the PI3K/Akt pathway by binding to PI3K. This blockage results in reduced Akt phosphorylation, which would diminish ACCSL activation if ACCSL is downstream of Akt or regulated by PI3K/Akt-mediated signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, Rapamycin disrupts the mTOR pathway which is associated with protein synthesis and cellular growth. If ACCSL is a downstream effector of the mTOR pathway, Rapamycin's action can lead to a decrease in ACCSL's activity by inhibiting mTOR signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK, SB203580 prevents the activation of p38 MAPK. If ACCSL function is modulated by p38 MAPK signaling, the inhibition of p38 MAPK by SB203580 would result in decreased ACCSL activity due to reduced signaling through this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that prevents the activation of the MAPK/ERK pathway. Inhibition of MEK by PD98059 leads to decreased ERK activation, which could result in a reduction of ACCSL activity if ACCSL is regulated by ERK or its downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of JNK, SP600125, by impeding JNK activity, can decrease the functional activity of ACCSL if ACCSL is a part of the JNK signaling cascade or is influenced by stress-activated protein kinase pathways that include JNK. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of MEK1/2, U0126 prevents the activation of the MAPK/ERK pathway. If ACCSL is involved in this pathway, the inhibition of MEK by U0126 would lead to decreased ACCSL activity by reducing signaling through ERK. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
As a Src family kinase inhibitor, PP2 can reduce the activity of Src family kinases. If ACCSL activity is modulated by Src kinase signaling, PP2's inhibition of these kinases can decrease ACCSL activity by reducing the phosphorylation of Src substrates that may interact with ACCSL. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
A ROCK inhibitor, Y-27632 can impact ACCSL by inhibiting the Rho kinase pathway, which regulates the actin cytoskeleton dynamics. If ACCSL is involved in signaling pathways related to actin cytoskeleton, Y-27632's action can lead to a decrease in ACCSL activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $47.00 $143.00 $680.00 | 16 | |
A selective FGFR inhibitor, PD173074 can inhibit the activity of FGFRs. If ACCSL activity is influenced by FGFR-mediated signaling pathways, PD173074 can lead to decreased ACCSL activity by preventing activation of the FGFRs and their downstream signaling. | ||||||